Andrea Eleazar, MHS

FDA fast-tracks pelareorep with bevacizumab and FOLFIRI for KRAS-mutant MSS metastatic colorectal cancer, after standout response and survival signals.

FDA reviews new drug applications for rivoceranib and camrelizumab as first-line treatments for advanced liver cancer, promising improved survival rates.

Discover the latest advancements in pancreatic cancer treatment, including targeted therapies and next-generation sequencing, transforming patient care and outcomes.

FDA reviews zanzalintinib and atezolizumab for metastatic colorectal cancer, offering hope for patients with limited treatment options.

FDA fast-tracks QTX-2101, an oral arsenic trioxide therapy, enhancing treatment accessibility for acute promyelocytic leukemia patients.

Discover how antibody-drug conjugates (ADCs) are transforming treatment strategies for gastrointestinal cancers, enhancing precision and patient outcomes.

Lirafugratinib shows promise as a second-line treatment for cholangiocarcinoma, achieving significant response rates and durable outcomes in clinical trials.

New trial data show onvansertib enhances treatment response and progression-free survival in RAS-mutated metastatic colorectal cancer, paving the way for future therapies.

FDA grants orphan drug designation to CTD402, a promising CAR T therapy for relapsed T-cell leukemia and lymphoma, enhancing treatment accessibility.

A novel neoadjuvant therapy combining PD-1 blockade and chemoradiotherapy shows promising results in treating patients with advanced rectal cancer with high Immunoscores.

The FDA approves a larger vial of nelarabine injection, enhancing treatment flexibility for T-cell leukemia in adults and children.

Atebimetinib shows promising 1-year survival rates in pancreatic cancer patients, potentially transforming treatment options with manageable safety profiles.

New trial results reveal zanidatamab significantly improves survival in HER2-positive advanced gastroesophageal adenocarcinoma, challenging existing treatment standards.

New research reveals comparable outcomes for STZ/5-FU and everolimus in treating advanced pancreatic neuroendocrine tumors, guiding personalized treatment strategies.

FDA approves Guardant360 CDx for identifying BRAF V600E-mutant colorectal cancer patients, enhancing precision therapy with encorafenib and cetuximab.

Combination therapies using PD-1/PD-L1 inhibitors enhance survival rates in relapsed/refractory acute lymphoblastic leukemia without added toxicity.

A new study reveals that combining ianalumab with ibrutinib offers promising results for chronic lymphocytic leukemia, enabling some patients to stop therapy.

Zenocutuzumab shows promising efficacy in advanced NRG1+ pancreatic and cholangiocarcinoma, offering hope for patients after disease progression.

New trial data reveals promising results for pelareorep and atezolizumab in treating advanced anal cancer, significantly improving response rates and duration.

New research highlights amivantamab's potential in enhancing treatment outcomes for RAS/BRAF wild-type metastatic colorectal cancer, addressing resistance to standard therapies.

Investigational therapy [212Pb]VMT-α-NET shows promising antitumor activity in advanced neuroendocrine tumors, with ongoing trials and favorable safety profile.

The FDA designates ICT01 as a breakthrough therapy for unfit AML patients, showcasing promising efficacy in early clinical trials.

New research reveals that ropeginterferon alfa-2b offers no significant benefits over observation after TKI cessation in chronic myeloid leukemia patients.

New data reveals that elraglusib combined with chemotherapy significantly improves survival rates in metastatic pancreatic cancer patients, offering hope for better outcomes.

Explore how community oncology reduces financial toxicity in cancer care, highlighting cost savings and quality benefits over hospital-based systems.

The FDA denies accelerated approval for tabelecleucel, highlighting ongoing challenges in treating EBV-positive posttransplant lymphoproliferative disease.

A novel oral fascin inhibitor, NP-G2-044, shows promise in treating pancreatic cancer, earning FDA orphan drug designation for innovative therapies.

New research highlights the benefits of physical activity, particularly walking, in reducing cancer-related fatigue and enhancing quality of life for colorectal cancer survivors.

The FDA designates ARB1002 as an orphan drug, highlighting its potential as a novel treatment for pancreatic cancer amid limited options.

The FDA designates zoldonrasib as a breakthrough therapy for KRAS G12D-mutated lung cancer, highlighting its promising efficacy and safety profile.